AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
By Editorial Team
AbbVie Inc. has reached a settlement in litigation with several drug manufacturers, effectively blocking generic versions of its immunosuppressant Rinvoq drug from entering the market until 2037. The settlement marks the conclusion of a legal battle where generic-drug makers were accused of infringing AbbVie’s patents.
The settlement agreement ensures that generic versions of Rinvoq will not be available for just over a decade, providing AbbVie with exclusive rights to market the drug until 2037. This move is expected to safeguard AbbVie’s market share and revenue from competition by generics.
The litigation involved multiple drug manufacturers, including Aurobindo Pharma Ltd., Hetero Labs Ltd., Intas Pharmaceuticals Ltd., Sandoz International GmbH, and Sun Pharmaceutical Industries Ltd. The legal dispute was brought before the U.S. District Court for the District of Delaware.
Legal representation in the case was provided by law firms such as Covington & Burling, Latham & Watkins, Morris James, and Morris Nichols. The case was presided over by Judge Maryellen Noreika.
AbbVie’s successful settlement in the Rinvoq litigation highlights the company’s commitment to protecting its intellectual property rights and maintaining its position in the pharmaceutical market. The agreement secures AbbVie’s exclusivity in marketing Rinvoq for an extended period, ensuring continued revenue and market dominance.
